These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24373193)

  • 1. Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breast.
    Choi EJ; Yun JA; Jeon EK; Won HS; Ko YH; Kim SY
    World J Surg Oncol; 2013 Dec; 11():314. PubMed ID: 24373193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of TMEM16A, PPFIA1, and FADD expression in invasive ductal carcinoma of the breast.
    Choi EJ; Yun JA; Jabeen S; Jeon EK; Won HS; Ko YH; Kim SY
    World J Surg Oncol; 2014 May; 12():137. PubMed ID: 24886289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
    Qiao W; Liu H; Guo W; Li P; Deng M
    Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases.
    Miše I; Vučić M
    Anal Cell Pathol (Amst); 2018; 2018():9432375. PubMed ID: 30151336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
    Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
    Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)-3β in invasive breast carcinomas.
    Mylona E; Vamvakaris I; Giannopoulou I; Theohari I; Papadimitriou C; Keramopoulos A; Nakopoulou L
    Histopathology; 2013 May; 62(6):899-907. PubMed ID: 23551536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome.
    Pare R; Shin JS; Lee CS
    Histopathology; 2016 Sep; 69(3):479-91. PubMed ID: 26843058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations of breast cancer FHIT gene with the incidence and prognosis of breast cancer.
    Fu Y; Shan X; Song W; Xu K; Jiao C; Zhang Q
    J BUON; 2019; 24(1):40-47. PubMed ID: 30941950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.
    Wazir U; Jiang WG; Yasaei H; Linne H; Newbold RF; Mokbel K
    Anticancer Res; 2013 May; 33(5):2185-9. PubMed ID: 23645774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
    Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
    Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aberrant expression and correlative analysis of P16 in breast cancers].
    Cui SP; Wang HL; Peng W; Liu HJ; Hou L; Zhang B
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):755-9. PubMed ID: 23073587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S; Staff S; Tanner M; Isola J
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas.
    Xu X; Jin H; Liu Y; Liu L; Wu Q; Guo Y; Yu L; Liu Z; Zhang T; Zhang X; Dong X; Quan C
    Diagn Pathol; 2012 Mar; 7():33. PubMed ID: 22455563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
    Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of bcl-2 expression among women with breast cancer in Libya.
    Ermiah E; Buhmeida A; Khaled BR; Abdalla F; Salem N; Pyrhönen S; Collan Y
    Tumour Biol; 2013 Jun; 34(3):1569-78. PubMed ID: 23417836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.